These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16784250)

  • 1. Idursulfase: I2S, iduronato-2-sulfatase.
    Drugs R D; 2006; 7(4):254-8. PubMed ID: 16784250
    [No Abstract]   [Full Text] [Related]  

  • 2. Idursulfase in Hunter syndrome treatment.
    Zareba G
    Drugs Today (Barc); 2007 Nov; 43(11):759-67. PubMed ID: 18174963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idursulfase: a poor risk-benefit balance in type II mucopolysaccharidosis.
    Prescrire Int; 2008 Jun; 17(95):109. PubMed ID: 18630351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idursulfase for the treatment of mucopolysaccharidosis II.
    Clarke LA
    Expert Opin Pharmacother; 2008 Feb; 9(2):311-7. PubMed ID: 18201153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
    Whiteman DA; Kimura A
    Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.
    Garcia AR; DaCosta JM; Pan J; Muenzer J; Lamsa JC
    Mol Genet Metab; 2007 Jun; 91(2):183-90. PubMed ID: 17459751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome).
    Sohn YB; Cho SY; Park SW; Kim SJ; Ko AR; Kwon EK; Han SJ; Jin DK
    Orphanet J Rare Dis; 2013 Mar; 8():42. PubMed ID: 23497636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome).
    Muenzer J; Wraith JE; Beck M; Giugliani R; Harmatz P; Eng CM; Vellodi A; Martin R; Ramaswami U; Gucsavas-Calikoglu M; Vijayaraghavan S; Wendt S; Puga AC; Ulbrich B; Shinawi M; Cleary M; Piper D; Conway AM; Kimura A
    Genet Med; 2006 Aug; 8(8):465-73. PubMed ID: 16912578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).
    Muenzer J; Gucsavas-Calikoglu M; McCandless SE; Schuetz TJ; Kimura A
    Mol Genet Metab; 2007 Mar; 90(3):329-37. PubMed ID: 17185020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II with and without comparison to placebo: systematic review and meta-analysis].
    Alegra T; Eizerik DP; de Cerqueira CC; Pereira TV; Dornelles AD; Schwartz IV
    Cad Saude Publica; 2013 Nov; 29 Suppl 1():S45-58. PubMed ID: 25402250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodistribution of Idursulfase Formulated for Intrathecal Use (Idursulfase-IT) in Cynomolgus Monkeys after Intrathecal Lumbar Administration.
    Chung JK; Brown E; Crooker B; Palmieri KJ; McCauley TG
    PLoS One; 2016; 11(10):e0164765. PubMed ID: 27764180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alvimopan: ADL 8-2698, ADL 82698, Entrareg, LY 246736.
    Drugs R D; 2006; 7(4):245-53. PubMed ID: 16784249
    [No Abstract]   [Full Text] [Related]  

  • 13. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.
    Barbier AJ; Bielefeld B; Whiteman DA; Natarajan M; Pano A; Amato DA
    Mol Genet Metab; 2013 Nov; 110(3):303-10. PubMed ID: 23988379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First treatment for Hunter syndrome.
    FDA Consum; 2006; 40(6):5. PubMed ID: 17333554
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical study of enzyme replacement therapy with idursulfase].
    Gutiérrez-Solana LG
    Rev Neurol; 2007 Feb; 44 Suppl 1():S7-S11. PubMed ID: 17345556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of idursulfase beta and idursulfase in vitro and in vivo.
    Kim C; Seo J; Chung Y; Ji HJ; Lee J; Sohn J; Lee B; Jo EC
    J Hum Genet; 2017 Feb; 62(2):167-174. PubMed ID: 27829684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II.
    Muenzer J; Hendriksz CJ; Fan Z; Vijayaraghavan S; Perry V; Santra S; Solanki GA; Mascelli MA; Pan L; Wang N; Sciarappa K; Barbier AJ
    Genet Med; 2016 Jan; 18(1):73-81. PubMed ID: 25834948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome).
    Pano A; Barbier AJ; Bielefeld B; Whiteman DA; Amato DA
    Orphanet J Rare Dis; 2015 Apr; 10():50. PubMed ID: 25902842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration.
    Xie H; Chung JK; Mascelli MA; McCauley TG
    PLoS One; 2015; 10(4):e0122453. PubMed ID: 25836678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
    Wraith JE
    Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.